<?xml version="1.0" encoding="UTF-8"?>
<table-wrap id="tbed13734-tbl-0002" xml:lang="en" content-type="TABLE" orientation="portrait" position="float">
 <label>TABLE 2</label>
 <caption>
  <p>Potential drug candidates for SARS‐CoV‐2 in clinical trials and their status in June 2020 based on clinicaltrials.gov database</p>
 </caption>
 <table frame="hsides" rules="groups">
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <col style="border-right:solid 1px #000000" span="1"/>
  <thead valign="top">
   <tr style="border-bottom:solid 1px #000000">
    <th align="left" valign="top" rowspan="1" colspan="1">ClinicalTrials.gov Identifier</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Intervention</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Mechanism of action</th>
    <th align="left" valign="top" rowspan="1" colspan="1">Status (Phase)</th>
   </tr>
  </thead>
  <tbody>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04343092</td>
    <td align="left" rowspan="1" colspan="1">Ivermectin (IVM)</td>
    <td align="left" rowspan="1" colspan="1">Inhibiting the importin (IMP) α/β receptor</td>
    <td align="left" rowspan="1" colspan="1">I</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04321096</td>
    <td align="left" rowspan="1" colspan="1">Camostat Mesilate</td>
    <td align="left" rowspan="1" colspan="1">Protease inhibition</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04324996</td>
    <td align="left" rowspan="1" colspan="1">Biological: NK cells, IL15‐NK cells,NKG2D CAR‐NK cells,ACE2 CAR‐NK cells, …</td>
    <td align="left" rowspan="1" colspan="1">Secreting The super IL15 superagonist and GM‐CSF neutralizing single‐chain variable fragment (scFv)</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04276688</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir/ritonavir; Ribavirin; Interferon Beta‐1B</td>
    <td align="left" rowspan="1" colspan="1">Inhibition of protease and viral mRNA synthesis</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04280588</td>
    <td align="left" rowspan="1" colspan="1">Fingolimod</td>
    <td align="left" rowspan="1" colspan="1">Modulation of Sphingosine 1‐phosphate receptor</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04273529</td>
    <td align="left" rowspan="1" colspan="1">Thalidomide</td>
    <td align="left" rowspan="1" colspan="1">Inhibition of Inflammatory cells and cytokines</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04288102</td>
    <td align="left" rowspan="1" colspan="1">Biological: Mesenchymal stem cells</td>
    <td align="left" rowspan="1" colspan="1">Possessing a comprehensive immunomodulatory function</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04317092</td>
    <td align="left" rowspan="1" colspan="1">Tocilizumab</td>
    <td align="left" rowspan="1" colspan="1">IL‐6‐mediated signalling inhibition</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04321993</td>
    <td align="left" rowspan="1" colspan="1">Lopinavir/ritonavir; Hydroxychloroquine sulphate; Baricitinib (janus kinase inhibitor); Sarilumab (anti‐IL‐6 receptor)</td>
    <td align="left" rowspan="1" colspan="1">Protease and janus kinase inhibition, anti‐IL‐6 receptor</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04313023</td>
    <td align="left" rowspan="1" colspan="1">PUL‐042 Inhalation Solution</td>
    <td align="left" rowspan="1" colspan="1">Reducing the severity of SARS‐CoV‐2</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04275245</td>
    <td align="left" rowspan="1" colspan="1">Meplazumab</td>
    <td align="left" rowspan="1" colspan="1">Host cell expressed CD147 antibody Inhibition of the S protein binding to the cell</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04279197</td>
    <td align="left" rowspan="1" colspan="1">Acetylcysteine</td>
    <td align="left" rowspan="1" colspan="1">Mucolytic agent</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04311177</td>
    <td align="left" rowspan="1" colspan="1">Losartan</td>
    <td align="left" rowspan="1" colspan="1">Angiotensin II receptor blocker</td>
    <td align="left" rowspan="1" colspan="1">II</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04292899</td>
    <td align="left" rowspan="1" colspan="1">Remdesivir</td>
    <td align="left" rowspan="1" colspan="1">RNA polymerase inhibition</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04325633</td>
    <td align="left" rowspan="1" colspan="1">Naproxen</td>
    <td align="left" rowspan="1" colspan="1">Prostaglandin G/H synthase inhibition</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04304313</td>
    <td align="left" rowspan="1" colspan="1">Sildenafil citrate</td>
    <td align="left" rowspan="1" colspan="1">cGMP‐specific phosphodiesterase type 5 (PDE5) inhibition</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04320615</td>
    <td align="left" rowspan="1" colspan="1">Tocilizumab (TCZ)</td>
    <td align="left" rowspan="1" colspan="1">IL‐6‐mediated signalling inhibition</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04315896</td>
    <td align="left" rowspan="1" colspan="1">Hydroxychloroquine</td>
    <td align="left" rowspan="1" colspan="1">Accumulation and raising the pH of the vacuole</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04317040</td>
    <td align="left" rowspan="1" colspan="1">CD24Fc</td>
    <td align="left" rowspan="1" colspan="1">Regulation of immune responses</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04261270</td>
    <td align="left" rowspan="1" colspan="1">ASC09F + Oseltamivir; Ritonavir + Oseltamivir; Oseltamivir</td>
    <td align="left" rowspan="1" colspan="1">Protease inhibition; neuraminidase inhibition</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04321616</td>
    <td align="left" rowspan="1" colspan="1">Hydroxychloroquine; Remdesivir</td>
    <td align="left" rowspan="1" colspan="1">Accumulation and raising the pH of the vacuole; RNA polymerase inhibition</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04315298</td>
    <td align="left" rowspan="1" colspan="1">Sarilumab</td>
    <td align="left" rowspan="1" colspan="1">IL‐6‐mediated signalling inhibition</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04324021</td>
    <td align="left" rowspan="1" colspan="1">Emapalumab</td>
    <td align="left" rowspan="1" colspan="1">Neutralizing the interferon‐gamma</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04252274</td>
    <td align="left" rowspan="1" colspan="1">Darunavir and cobicistat</td>
    <td align="left" rowspan="1" colspan="1">Protease inhibition‐ cytochrome P450 3A (CYP3A) isoforms inhibition</td>
    <td align="left" rowspan="1" colspan="1">III</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04308317</td>
    <td align="left" rowspan="1" colspan="1">Tetrandrine</td>
    <td align="left" rowspan="1" colspan="1">Not described</td>
    <td align="left" rowspan="1" colspan="1">IV</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04286503</td>
    <td align="left" rowspan="1" colspan="1">Carrimycin</td>
    <td align="left" rowspan="1" colspan="1">Macrolide antibiotic</td>
    <td align="left" rowspan="1" colspan="1">IV</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04254874</td>
    <td align="left" rowspan="1" colspan="1">Arbidol Hydrochloride combined with Interferon atomization</td>
    <td align="left" rowspan="1" colspan="1">Dual‐acting direct anti‐viral/host‐targeting</td>
    <td align="left" rowspan="1" colspan="1">IV</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04263402</td>
    <td align="left" rowspan="1" colspan="1">Methylprednisolone</td>
    <td align="left" rowspan="1" colspan="1">Corticosteroid</td>
    <td align="left" rowspan="1" colspan="1">IV</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04252885</td>
    <td align="left" rowspan="1" colspan="1">Umifenovir (Arbidol)</td>
    <td align="left" rowspan="1" colspan="1">Dual‐acting direct anti‐viral/host‐targeting</td>
    <td align="left" rowspan="1" colspan="1">IV</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04255017</td>
    <td align="left" rowspan="1" colspan="1">Umifenovir (Arbidol); Oseltamivir; Lopinavir/ritonavir</td>
    <td align="left" rowspan="1" colspan="1">Dual‐acting direct anti‐viral/host‐targeting Neuraminidase inhibition; protease inhibition</td>
    <td align="left" rowspan="1" colspan="1">IV</td>
   </tr>
   <tr>
    <td align="left" rowspan="1" colspan="1">NCT04291729</td>
    <td align="left" rowspan="1" colspan="1">Drug: Ganovo (Danoprevir) + ritonavir ± Interferon nebulization</td>
    <td align="left" rowspan="1" colspan="1">Protease inhibition</td>
    <td align="left" rowspan="1" colspan="1">IV</td>
   </tr>
  </tbody>
 </table>
 <permissions>
  <copyright-holder>John Wiley &amp; Sons, Ltd</copyright-holder>
  <license>
   <license-p>This article is being made freely available through PubMed Central as part of the COVID-19 public health emergency response. It can be used for unrestricted research re-use and analysis in any form or by any means with acknowledgement of the original source, for the duration of the public health emergency.</license-p>
  </license>
 </permissions>
</table-wrap>
